(Q34501946)

2 August 2017

1 reference

title

The treatment of limited small cell lung cancer: a report of the progress made and future prospects (English)

1 reference

2 August 2017

1 reference

Turrisi AT

1

1 reference

PubMed ID

11803144

2 August 2017

Sherman CA

series ordinal

2

1 reference

2 August 2017

1 January 2002

1 reference

European Journal of Cancer

2 August 2017

1 reference

2 August 2017

38

1 reference

2 August 2017

2

1 reference

2 August 2017

279-291

1 reference

Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Management of small-cell cancer of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a So

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Is bone marrow examination in small-cell lung cancer really necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Neurotoxicity in long-term survivors of small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Brain irradiation and systemic chemotherapy for small-cell lung cancer: dangerous liaisons?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

Ganglioside expression in lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900364-1

7 January 2021

10.1016/S0959-8049(01)00364-1

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11803144